Yolaçan, RamazanKaya, BekirÜzel, AliKarabulut, ÜmitUçmak, FeyzullahKaya, Muhsin2024-04-242024-04-2420231303-66292149-0600https://doi.org/10.17941/agd.1333370https://search.trdizin.gov.tr/yayin/detay/1213621https://hdl.handle.net/11468/28571Interferon ?-1a is an immunomodulatory drug widely used in the treatment of multiple sclerosis. Liver dysfunction is a common side effect of this drug and usually develops within the first 6 months of starting interferon therapy. Here, we present our case who developed hepatotoxicity secondary to interferon ?-1a treatment.eninfo:eu-repo/semantics/openAccessHepatotoxicity case due to interferon beta-1a useHepatotoxicity case due to interferon beta-1a useArticle223164167121362110.17941/agd.1333370